BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

21 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.EBI
Cellzome
A quantitative analysis of kinase inhibitor selectivity.EBI
Ambit Biosciences
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.EBI
University of Oxford
In vitro and in silico studies on substrate recognition and acceptance of human PKMYT1, a Cdk1 inhibitory kinase.EBI
Martin-Luther-University Halle-Wittenberg
Comprehensive analysis of kinase inhibitor selectivity.EBI
Ambit Biosciences
Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.EBI
Pfizer
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).EBI
Ambit Biosciences
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.EBI
Eli Lilly and Company
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.EBI
Johann Wolfgang Goethe University
Structure-Based Drug Design of 2-Amino-[1,1'-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1-Amplified Breast Cancer.EBI
Jinan University
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.EBI
Repare Therapeutics
A small molecule-kinase interaction map for clinical kinase inhibitors.EBI
Ambit Biosciences
Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1.EBI
Martin-Luther-University Halle-Wittenberg
Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II.EBI
Martin-Luther-University Halle-Wittenberg
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.EBI
Moffitt Cancer Center
Hexone glucokinase inhibitor and use thereofBDB
Shandong Xuanzhu Pharma Co.
USE OF HPK1 INHIBITOR IN TREATMENT OF INTERFERON-RELATED DISEASESBDB
Asclepieion Pharmaceutical
4-(2-PYRAZOLO[3,4-B]PYRIDINE-5-YL)ETHYNYL-2-PYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORSBDB
IP2IPO Innovations
Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitorsBDB
Forschungsverbund Berlin
Cyanopyrrolidines as dub inhibitors for the treatment of cancerBDB
Mission Therapeutics
Methods of identifying SENP1 inhibitorsBDB
City of Hope